Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
Won Hyeok Choe, Kijeong Kim, So-Young Lee, Yu-Min Choi, So Young Kwon, Jeong Han Kim, Bum-Joon Kim
Won Hyeok Choe, So Young Kwon, Jeong Han Kim, Department of Internal Medicine, Konkuk University School of Medicine, Seoul 05030, South Korea
Kijeong Kim, Department of Microbiology, College of Medicine, Chung-Ang University, Seoul 06974, South Korea
So-Young Lee, Yu-Min Choi, Bum-Joon Kim, Department of Biomedical Sciences, Microbiology and Immunology, Liver Research Institute, Cancer Research Institute and SNUMRC, College of Medicine, Seoul National University, Seoul 03080, South Korea
Author contributions: Choe WH and Kim K contributed equally to this work; Kim K and Kim BJ contributed to study conception and design, and designed and performed experiments; Choe WH, Kim JH, and Kwon SY contributed to collection of clinical data; Choe WH, Kim K, Lee SY, Choi YM, and Kim BJ contributed to data acquisition, data analysis and interpretation; Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, and Kim BJ contributed to writing of article, editing, reviewing and final approval of article.
Institutional review board statement: Based on the Declaration of Helsinki, the Institutional Review Board of Konkuk University Hospital approved the retrospective use of the clinical, biochemical, and radiographic data for the present study.
Informed consent statement: The requirements for informed consent were waived due to the retrospective design.
Conflict-of-interest statement: The authors declare they have no potential conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read and checked the STROBE checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Bum Joon Kim, PhD, Professor, Department of Biomedical Sciences, Microbiology and Immunology, Liver Research Institute, Cancer Research Institute and SNUMRC, College of Medicine, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. kbumjoon@snu.ac.kr
Telephone: +82-2-7408315 Fax: +82-2-7430881
Received: June 17, 2019
Peer-review started: June 17, 2019
First decision: July 21, 2019
Revised: July 30, 2019
Accepted: August 19, 2019
Article in press: August 19, 2019
Published online: September 7, 2019
